Savara Q2 Earnings: Increased Loss Amid R&D Investments, Strong Liquidity Position

Savara Inc. reported a Q2 net loss of $30.4 million due to increased R&D investments in its primary drug candidate. The company's cash and cash equivalents totaled $17.4 million, with short-term investments at $129 million. Savara's management remains focused on advancing clinical trials and securing regulatory approvals, with plans to potentially raise additional capital for future development and commercialization efforts.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported a net loss of $30.4 million for the second quarter of 2025. The loss, compared to $22.2 million for the same period in 2024, was driven by increased research and development (R&D) expenses and general and administrative costs [1].

The company's cash and cash equivalents totaled $17.4 million, with short-term investments amounting to $129 million as of June 30, 2025 [2]. Savara's management remains focused on advancing clinical trials and securing regulatory approvals for its primary drug candidate, MOLBREEVI. The company anticipates incurring significant expenses as it continues the clinical development of MOLBREEVI and seeks regulatory approval [1].

Savara recently reached alignment with the U.S. Food and Drug Administration (FDA) on the information needed for resubmitting its Biologics License Application (BLA) for MOLBREEVI. The company plans to resubmit the BLA in December 2025 with Fujifilm as the drug substance manufacturer and will request Priority Review [2]. Additionally, Savara anticipates submitting the MOLBREEVI Marketing Authorization Applications to the European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in the first quarter of 2026 [2].

Savara's management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs and effectively advancing product candidates to approval and commercialization. The company operates by outsourcing its manufacturing and most clinical operations, allowing it to focus on its core competencies in R&D [1].

References:
[1] https://www.tradingview.com/news/tradingview:a504f306aa4e0:0-savara-inc-sec-10-q-report/
[2] https://investors.savarapharma.com/news/news-details/2025/Savara-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Business-Update/default.aspx